HDAC (Histone Deacetylase) Inhibitors Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, China - Size and Forecast 2023-2027

Published: Jan 2023 Pages: 157 SKU: IRTNTR72719

HDAC (Histone Deacetylase) Inhibitors Market Forecast 2023-2027

The HDAC (histone deacetylase) inhibitors market is estimated to increase by USD 172.61 million between 2022 and 2027. The size of the market is forecast to grow at a CAGR of 7.73%. The growth of the market depends on several factors, including high target affinity and specificity, high prevalence of oncology indications, and the development of novel drug delivery systems and combination therapies.

What will be the size of the HDAC (Histone Deacetylase) Inhibitors Market During the Forecast Period?

To learn more about this report, Download Report Sample

Market: Key Drivers, Trends, Challenges, and Customer Landscape

The high target affinity and specificity are notably driving the market growth, although factors such as high costs associated with treatment may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Driver

The high target affinity and specificity is one of the key drivers supporting the market growth. HDAC inhibitors are known to demonstrate promising results in cancer treatments, which is further promotes the R&D teams to conduct research for other applications such as neurologic conditions. These inhibitors have the quality of inducing differentiation, cell-cycle arrest, and apoptosis.

Furthermore, they inhibit migration, invasion, and angiogenesis in many cancer cell lines. Unlike conventional therapies, these drugs work directly on the target, and hence, their efficacy is higher than the conventional treatments. The mechanism of action (MoA) of this drug class is target-specific, which makes it a potential single solution for many diseases, including neurological disorders and carcinomas, among both medical practitioners as well as patients, which drives the market growth.

Significant Trend

Growing awareness about cancer is the primary trend in the market. Various international and national-level campaigns are conducted to increase awareness about cancer and help early detection of the disease. For instance, organizations such as the American Social Health Association (ASHA) and the National Cervical Cancer Coalition (NCCC) implement initiatives to create awareness about the prevention and control of cervical cancer. Similarly, the CDC provides guidelines and conducts awareness programs to screen and vaccinate underserved individuals with cervical cancer.

Furthermore, Cancer Breakthroughs 2020, previously known as Cancer Moonshot 2020, is an initiative taken by the US government in 2016 for the development of research on vaccine-based immunotherapies to fight cancer. The aim of this project is to make therapies available to more patients while detecting the disease at an early stage. By inviting the pharmaceutical players to join the initiative, the Cancer Breakthroughs 2020 program plans on making the targeted therapies one of the major areas of focus of this project. These initiatives are expected to increase awareness about cancer and the available treatments, including various targeted and immunotherapies treating cancer during the forecast period.

Major Challenge

High costs associated with treatment is one of the factors hindering the market growth. Many HDAC inhibitors are used in combination with substitutes such as surgery and radiation therapies, which increases the cost burden of the treatment significantly. The high cost of cancer treatment is mainly due to hospitalization, laboratory tests, and novel therapies. In developing and underdeveloped countries, the cost of treatment with HDAC inhibitors is very high.

For instance, belinostat (BELEODAQ) costs around USD1,976.75 for one unit of 500 mg of powder for injection. Also, according to the CDC, the cost of cancer care continues to rise and is expected to reach almost USD174 billion by 2020. Such high treatment costs act as a barrier to drug adoption, which reduces the patient base and poses a challenge to market growth.

Key Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Who are the Major HDAC (Histone Deacetylase) Inhibitors Market Players?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Onxeo SA - Onxeo SA is a public company that is headquartered in France. It is a regional company that generated a revenue of USD 12.13 million and had around 25 employees. Its revenue from the global histone deacetylase (HDAC) inhibitors market contributes to its overall revenues, along with its other offerings, but is not a key revenue stream for the company. The company offers farydak deacetylase inhibitor which is used to treat multiple myeloma cancer treatment.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market players, including:

  • Bristol Myers Squibb Co.
  • Celleron Therapeutics Ltd.
  • Curis Inc.
  • Huya Bioscience International LLC
  • InvivoGen Corp.
  • Italfarmaco Spa
  • Medivir AB
  • Merck and Co. Inc.
  • Novartis AG
  • Shenzhen Chipscreen Biotechnology Co. Ltd.
  • Syndax Pharmaceuticals Inc.
  • Tokyo Chemical Industry Co. Ltd.
  • Viracta Therapeutics Inc.
  • Xynomic Pharmaceuticals (Nanjing) Co. Ltd.
  • Cetya Therapeutics Inc.

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Market?

The market share growth of the oral HDAC inhibitors segment will be significant during the forecast period. The strong pipeline of oral HDAC inhibitors is the major factor driving the growth of the segment. This type of HDAC inhibitor is taken orally or through the mouth. Currently, more than ten HDAC inhibitors, which can be administered through oral RoA, are in the pipeline. The presence of such a strong pipeline will aid in the launch of new drugs for administration via the oral route during the forecast period, which will increase the product portfolio of the oral HDAC inhibitors segment. This, in turn, will result in market growth.

Get a glance at the market contribution of various segments Request a PDF Sample

The oral HDAC inhibitors segment was valued at USD 230.76 million in 2017 and continued to grow until 2021. The oral route is the easiest way to administer a drug. However, the cost of these drugs is very high. Therefore, to overcome the high-cost challenge of these drugs, many companies and government or non-government organizations are providing financial assistance through patient assistance programs. Therefore, a strong pipeline coupled with the availability of patient assistance programs is expected to drive the growth of the segment.

Which are the Key Regions for the Market?

For more insights on the market share of various regions Request PDF Sample now!

North America is estimated to contribute 32% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The high prevalence of cancer and the increasing need for innovative medications are the major factors driving the market growth in this region. Although the US has several approved therapies, various side effects associated with most of them create a huge demand for enhanced therapies. Hence, HDAC inhibitors are attracting extensive R&D attention in the country due to their target-specific treatment approach. These extensive R&D efforts get further support from an established R&D platform and the presence of all major oncology vendors in the country, resulting in a strong pipeline. Currently, a few molecules are in the late stages of development. Hence, late-stage molecules in the pipeline are expected to be launched during the forecast period, which will expand the product portfolio in the market and drive market growth in the region. 

Many pharmaceutical companies are headquartered in the US, thus making it a hub for the pharmaceutical industry, which further strengthens the drug distribution network in the country. Hence, the US is the strongest player in the market, and the majority of the market share of North America is attributed to the country, thus resulting in fast saturation of the market. Hence, the HDAC inhibitors market in North America is growing at a lower CAGR than the global market.

Segment Overview

The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

  • Route Of Administration Outlook (USD Million, 2017 - 2027)
    • Oral HDAC inhibitors
    • Parenteral HDAC inhibitors
  • Application Outlook (USD Million, 2017 - 2027)
    • Hospital pharmacies
    • Retail pharmacies
    • Online pharmacies
    • Others
  • Region Outlook (USD Million, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of World (ROW)
      • Brazil
      • Argentina
      • Rest of the Middle East & Africa

Market Analyst Overview

The market is segmented based on classification into Class I HDACs, Class II HDACs, Class III HDACs, and Others. The route of Administration includes Oral, Injectable, and Others, with End Users being Hospitals, home care, Specialty Clinics, and Others. Distribution Channels encompass Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and Others. The market focuses on Targeted modes of therapies, Novel drugs, and therapies, with a prevalent concern for chronic disorders and Anti-cancer agents. It includes Chemotherapy agents, T-cell lymphoma, and considerations for Personal disposable income. Market growth rates, Trade regulations, Import-export analyses, and Production analyses are key components, along with Value chain optimization and the Impact of domestic and localized market players.

Market regulations and Strategic market growth analyses are integral, along with Category market growths, Application niches, and Product launches. Insights into Market overview, Strategic decisions, Identification of core market applications, and Patient Epidemiology Analysis are crucial. This includes Incidence, Mortality, and Adherence rates. Some of the major vendors in the market include Crystal Genomics Inc, Shenzhen Chipscreen Biosciences Co, Spectrum Pharmaceuticals, Inc, Merck & Co, FORUM Pharmaceuticals Inc, Eisai Co, REGENACY PHARMACEUTICALS, INC, Karyopharm, Aurobindo Pharma, CARDIFF ONCOLOGY, Wellness Pharma International, and MEI Pharma, Inc.

HDAC (Histone Deacetylase) Inhibitors Market Scope

Report Coverage

Details

Page number

157

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 7.73%

Market growth 2023-2027

USD 172.61 million

Market structure

Concentrated

YoY growth 2022-2023(%)

6.74

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 32%

Key countries

US, Canada, UK, Germany, and China

Competitive landscape

 Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Acrotech Biopharma Inc., AstraZeneca Plc, Bio Techne Corp., BioVision Inc., Bristol Myers Squibb Co., Celleron Therapeutics Ltd., Curis Inc., Huya Bioscience International LLC, InvivoGen Corp., Italfarmaco Spa, Medivir AB, Merck and Co. Inc., Novartis AG, Onxeo SA, Shenzhen Chipscreen Biotechnology Co. Ltd., Syndax Pharmaceuticals Inc., Tokyo Chemical Industry Co. Ltd., Viracta Therapeutics Inc., Xynomic Pharmaceuticals (Nanjing) Co. Ltd., and Cetya Therapeutics Inc.

Market dynamics

Parent market analysis, Market forecasting, market growth and trends, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our market research report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Market Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
  • Precise estimation of the size of the market size and its contribution to the parent market
  • Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
  • Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
  • Thorough market growth analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive market analysis and report on the factors that will challenge the market research and growth of market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global HDAC (histone deacetylase) inhibitors market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global HDAC (histone deacetylase) inhibitors market 2017 - 2021 ($ million)
    • 4.2 Route of administration Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Route of administration Segment 2017 - 2021 ($ million)
    • 4.3 Distribution Channel Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Route of Administration

    • 6.1 Market segments
      • Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%)
    • 6.2 Comparison by Route of Administration
      • Exhibit 32: Chart on Comparison by Route of Administration
      • Exhibit 33: Data Table on Comparison by Route of Administration
    • 6.3 Oral HDAC inhibitors - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Oral HDAC inhibitors - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Oral HDAC inhibitors - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Oral HDAC inhibitors - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Oral HDAC inhibitors - Year-over-year growth 2022-2027 (%)
    • 6.4 Parenteral HDAC inhibitors - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Parenteral HDAC inhibitors - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Parenteral HDAC inhibitors - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Parenteral HDAC inhibitors - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Parenteral HDAC inhibitors - Year-over-year growth 2022-2027 (%)
    • 6.5 Market opportunity by Route of Administration
      • Exhibit 42: Market opportunity by Route of Administration ($ million)

    7 Market Segmentation by Distribution Channel

    • 7.1 Market segments
      • Exhibit 43: Chart on Distribution Channel - Market share 2022-2027 (%)
      • Exhibit 44: Data Table on Distribution Channel - Market share 2022-2027 (%)
    • 7.2 Comparison by Distribution Channel
      • Exhibit 45: Chart on Comparison by Distribution Channel
      • Exhibit 46: Data Table on Comparison by Distribution Channel
    • 7.3 Hospital pharmacies - Market size and forecast 2022-2027
      • Exhibit 47: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 48: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 49: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
      • Exhibit 50: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
    • 7.4 Retail pharmacies - Market size and forecast 2022-2027
      • Exhibit 51: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 52: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 53: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
      • Exhibit 54: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)
    • 7.5 Online pharmacies - Market size and forecast 2022-2027
      • Exhibit 55: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 56: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 57: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%)
      • Exhibit 58: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%)
    • 7.6 Others - Market size and forecast 2022-2027
      • Exhibit 59: Chart on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 60: Data Table on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 61: Chart on Others - Year-over-year growth 2022-2027 (%)
      • Exhibit 62: Data Table on Others - Year-over-year growth 2022-2027 (%)
    • 7.7 Market opportunity by Distribution Channel
      • Exhibit 63: Market opportunity by Distribution Channel ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 65: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 66: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 67: Chart on Geographic comparison
      • Exhibit 68: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 69: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 70: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 71: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 72: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 73: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 74: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 75: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 76: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 77: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 78: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 79: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 80: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 85: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 86: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 87: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 88: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 Canada - Market size and forecast 2022-2027
      • Exhibit 89: Chart on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 90: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 91: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 92: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 9.9 UK - Market size and forecast 2022-2027
      • Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.10 Germany - Market size and forecast 2022-2027
      • Exhibit 97: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 98: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 99: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 100: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.11 China - Market size and forecast 2022-2027
      • Exhibit 101: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 102: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 103: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 104: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 105: Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 106: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 107: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 108: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 109: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 110: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 111: Matrix on vendor position and classification
            • 12.3 Acrotech Biopharma Inc.
              • Exhibit 112: Acrotech Biopharma Inc. - Overview
              • Exhibit 113: Acrotech Biopharma Inc. - Product / Service
              • Exhibit 114: Acrotech Biopharma Inc. - Key offerings
            • 12.4 AstraZeneca Plc
              • Exhibit 115: AstraZeneca Plc - Overview
              • Exhibit 116: AstraZeneca Plc - Product / Service
              • Exhibit 117: AstraZeneca Plc - Key news
              • Exhibit 118: AstraZeneca Plc - Key offerings
            • 12.5 Bristol Myers Squibb Co.
              • Exhibit 119: Bristol Myers Squibb Co. - Overview
              • Exhibit 120: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 121: Bristol Myers Squibb Co. - Key news
              • Exhibit 122: Bristol Myers Squibb Co. - Key offerings
            • 12.6 Celleron Therapeutics Ltd.
              • Exhibit 123: Celleron Therapeutics Ltd. - Overview
              • Exhibit 124: Celleron Therapeutics Ltd. - Key offerings
            • 12.7 Curis Inc.
              • Exhibit 125: Curis Inc. - Overview
              • Exhibit 126: Curis Inc. - Product / Service
              • Exhibit 127: Curis Inc. - Key offerings
            • 12.8 Huya Bioscience International LLC
              • Exhibit 128: Huya Bioscience International LLC - Overview
              • Exhibit 129: Huya Bioscience International LLC - Product / Service
              • Exhibit 130: Huya Bioscience International LLC - Key offerings
            • 12.9 Italfarmaco Spa
              • Exhibit 131: Italfarmaco Spa - Overview
              • Exhibit 132: Italfarmaco Spa - Product / Service
              • Exhibit 133: Italfarmaco Spa - Key offerings
            • 12.10 Medivir AB
              • Exhibit 134: Medivir AB - Overview
              • Exhibit 135: Medivir AB - Product / Service
              • Exhibit 136: Medivir AB - Key offerings
            • 12.11 Merck and Co. Inc.
              • Exhibit 137: Merck and Co. Inc. - Overview
              • Exhibit 138: Merck and Co. Inc. - Business segments
              • Exhibit 139: Merck and Co. Inc. - Key news
              • Exhibit 140: Merck and Co. Inc. - Key offerings
              • Exhibit 141: Merck and Co. Inc. - Segment focus
            • 12.12 Novartis AG
              • Exhibit 142: Novartis AG - Overview
              • Exhibit 143: Novartis AG - Business segments
              • Exhibit 144: Novartis AG - Key offerings
              • Exhibit 145: Novartis AG - Segment focus
            • 12.13 Onxeo SA
              • Exhibit 146: Onxeo SA - Overview
              • Exhibit 147: Onxeo SA - Product / Service
              • Exhibit 148: Onxeo SA - Key offerings
            • 12.14 Shenzhen Chipscreen Biotechnology Co. Ltd.
              • Exhibit 149: Shenzhen Chipscreen Biotechnology Co. Ltd. - Overview
              • Exhibit 150: Shenzhen Chipscreen Biotechnology Co. Ltd. - Product / Service
              • Exhibit 151: Shenzhen Chipscreen Biotechnology Co. Ltd. - Key offerings
            • 12.15 Syndax Pharmaceuticals Inc.
              • Exhibit 152: Syndax Pharmaceuticals Inc. - Overview
              • Exhibit 153: Syndax Pharmaceuticals Inc. - Key offerings
            • 12.16 Viracta Therapeutics Inc.
              • Exhibit 154: Viracta Therapeutics Inc. - Overview
              • Exhibit 155: Viracta Therapeutics Inc. - Product / Service
              • Exhibit 156: Viracta Therapeutics Inc. - Key offerings
            • 12.17 Xynomic Pharmaceuticals (Nanjing) Co. Ltd.
              • Exhibit 157: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. - Overview
              • Exhibit 158: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. - Product / Service
              • Exhibit 159: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 160: Inclusions checklist
                • Exhibit 161: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 162: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 163: Research methodology
                • Exhibit 164: Validation techniques employed for market sizing
                • Exhibit 165: Information sources
              • 13.5 List of abbreviations
                • Exhibit 166: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              hdac (histone deacetylase) inhibitors market market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis